[Low molecular weight heparin: favorable effect profile for prevention and therapy of venous thrombosis].
This short review addresses the use of low molecular weight heparins (LMWH) for prevention and treatment of venous thromboembolism. In general surgery, the once daily subcutaneous (sc) administration of LMWH provides at least as much protection against thrombosis as 2 to 3 times 5000 IU sc of unfractionated heparin (UFH). In high-risk orthopedic surgery LMWH prophylaxis is definitely more efficient than conventional regimens with UFH or dextran. Several studies convincingly demonstrate that LMWH may be at least as good as UFH for the treatment of deep venous thrombosis.
Marbet
G A
GA
Gerinnungs- und Fibrinolyselaboratorium, Kantonsspital, Basel.
D004305:Dose-Response Relationship, Drug; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D011183:Postoperative Complications / Q000188:drug therapy / Q000517:prevention & control; D013924:Thrombophlebitis / Q000188:drug therapy / Q000517:prevention & control*
D006495:Heparin, Low-Molecular-Weight
Niedermolekulare Heparine: vorteilhaftes Wirkungsprofil für Prophylaxe und Therapie venöser Thrombosen.